°¡Å縯´ëÇб³ ¿©Àǵµ¼º¸ðº´¿ø Ç÷¾×³»°ú ¾ö±â¼º ±³¼ö°¡ Áö³´Þ 19~20ÀÏ ¹«ÁÖ¸®Á¶Æ®ÄÁº¥¼Ç¼¾ÅÍ¿¡¼ °³ÃÖµÈ Á¦14Â÷ Á¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ µ¿°èÇмú´ëȸ¿¡¼ ‘Gemtuzumab ozogamicin offers durable remission in elderly patients with AML who receive stem cell transplantation’À̶ó´Â ÁÖÁ¦·Î ÃÖ¿ì¼ö¿¬Á¦»óÀ» ¼ö»óÇß´Ù.
ÃÖ¿ì¼ö¿¬Á¦»óÀº ÇÐȸ±â°£ ¹ßÇ¥µÈ ÃÑ 43ÆíÀÇ ±¸¿¬ ¹× Æ÷½ºÅÍ Áß ³»¿ëÀÌ °¡Àå ¿ì¼öÇÏ°í ÀÇÇйßÀü¿¡ ±â¿©ÇÒ ¼ö ÀÖ´Â ¿¬Á¦ 1ÆíÀ» Àü¹®°¡ÀÇ ½É»ç¿¡ ÀÇÇØ ¼±Á¤ÇÏ´Â »óÀÌ´Ù.
¾ö±â¼º ±³¼ö´Â À̹ø ±¸¿¬À» ÅëÇØ ³ëÀμº ±Þ¼º°ñ¼ö¼º¹éÇ÷º´ ȯÀÚÀÇ Ä¡·á¿¡ ÀÖ¾î Ãֱ٠ǥÀûÇ×¾ÏÁ¦·Î °¢±¤À» ¹Þ°í ÀÖ´Â gemtuzumab ozogamicin (mylotarg®)ÀÇ °üÇØÀ¯µµÇ×¾ÏÁ¦·ÎÀÇ »ç¿ëÀÌ À̵é ȯÀÚµéÀÇ Á¶Ç÷¸ð¼¼Æ÷ ÀÌ½Ä ¼ºÀûÀ» Çâ»ó ½Ãų ¼ö ÀÖ´Ù´Â ³»¿ëÀ» ¹ßÇ¥Çß´Ù.
ƯÈ÷ À̹ø ¿¬±¸´Â ³ëÀÎ ±Þ¼º°ñ¼ö¼º¹éÇ÷º´ ȯÀÚÀÇ Á¶Ç÷¸ð¼¼Æ÷ À̽Ŀ¡ ÀÖ¾î ÀÌ ¾àÁ¦ÀÇ ¿ªÇÒÀ» óÀ½À¸·Î ºÐ¼®Çß´Ù´Â Á¡¿¡¼ Àǹ̰¡ Å©´Ù.
ÇÑÆí ¾ö±â¼º ±³¼ö´Â ´ëÇѳ»°úÇÐȸ, ´ëÇÑÇ÷¾×ÇÐȸ, ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ, ´ëÇѸ鿪ÇÐȸ µîÀÇ ÇÐȸȰµ¿°ú ÀϹÝÇ÷¾×Áúȯ ºÐ¾ß¿¡¼ ´Ù¾çÇÑ ¿¬±¸ ¹× Áø·á È°µ¿À» ÇÏ°í ÀÖ´Ù.